Allogeneic bone marrow-derived product in development for stroke-related disabilities.

Dainippon Sumitomo Pharma (DSP) negotiated an option to exclusive U.S. and Canadian marketing rights to SanBio’s early clinical-stage allogeneic cell therapy candidate SB623. The product was recently granted FDA clearance to start in a clinical trial as a potential treatment for stroke-related disabilities. DSP says it will decide on whether to take its U.S. and Canadian marketing option once a Phase I/IIa study has been completed.

SanBio is exploiting its NDR™ technology to develop bone marrow-derived allogeneic cell therapies for treating neurological disorders. The firm’s pipeline includes SB623 for the treatment of stroke, spinal cord injury, and Parkinson’s disease, along with SB618 for the treatment of multiple sclerosis and spinal cord injury, and SB308 for the treatment of muscular dystrophy and trauma.

SanBio claims preclinical studies confirm that when injected into neural tissue, SB623 cells help  restore function to damaged neurons associated with stroke, spinal cord injury, and Parkinson’s disease. The company also believes SB623 may be useful in other diseases and conditions associated with neurological deficit such as traumatic brain injury, Huntington disease, and amyotrophic lateral sclerosis. SanBio is developing SB618 for the treatment of conditions that affect the myelin sheath of neurons such as multiple sclerosis and spinal cord injury. The third product, SB308, uses donor bone marrow-derived cells to stimulate muscle regeneration, and is in preclinical development as a potential approach to treating conditions such as muscular dystrophy, and to promote recovery from trauma and surgery.

Previous articleSanofi-Aventis Bypasses Genzyme Board and Takes $18.5B Bid Directly to Shareholders
Next articleWatson Invests $30M in Moksha8 and Forms Marketing Partnership for Brazil and Mexico